Decavanadate Compound Displays In Vitro and In Vivo Antitumor Effect on Melanoma Models

The efficacy of available treatments for melanoma is limited by side effects and the rapidly emerging resistance to treatment. In this context, the decavanadate compounds represent promising tools to design efficient therapeutic agents. In our study, we synthesized a dimagnesium disodium decavanadate icosahydrate compound (Mg<sub>2</sub>Na<sub>2</sub>V<sub>10</sub>O<sub>28</sub>·20H<sub>2</sub>O) and investigated its structure stability as well as its antimelanoma effects. Results showed that the Mg<sub>2</sub>Na<sub>2</sub>V<sub>10</sub>O<sub>28</sub>·20H<sub>2</sub>O compound is structured in a monoclinic system with the space group C2/c, stabilized by oxygen vertices, hydrogen bonds, and van der Waals interactions. Interestingly, we found that this newly synthesized compound reduced the viability of human (IGR39, IGR37, and SKMEL28) and murine (B16-F10) melanoma cells in a dose-dependent manner. The IC<sub>50</sub> values ranged from 7.3 to 18 μM after 24 h and decreased to 1.4 μM after 72 h of treatment. Notably, this effect was more important than that of cisplatin (IC<sub>50</sub> = 3 μM after 72 h of treatment), a chemotherapeutic agent, commonly used in the treatment of malignant melanoma. Furthermore, the cytotoxicity of the decavanadate compound was relatively weak on normal human keratinocytes (HaCaT), with a light effect (IC<sub>50</sub> >> 70 μM) observed after 24 h of treatment. Thus, the Mg<sub>2</sub>Na<sub>2</sub>V<sub>10</sub>O<sub>28</sub>·20H<sub>2</sub>O compound displayed an advantage over cisplatin, which was reported to be much more aggressive to the keratinocyte cell line (IC<sub>50</sub> = 23.9 μM). Moreover, it inhibited dose-dependently the adhesion of IGR39 cells to collagen (IC<sub>50</sub> = 2.67 μM) and fibronectin, as well as their migration with an IC<sub>50</sub> value of 2.23 μM. More interestingly, its in vivo administration to B16-F10 allografted mice, at the nontoxic dose of 50 μg (2.5 mg/kg), prevented and suppressed by 70% the tumor growth, compared to the nontreated mice. Moreover, this compound has also allowed a recovery against inflammation induced in mice by a mixture of DMBA and croton oil. Thus, all our results showed the potential of the Mg<sub>2</sub>Na<sub>2</sub>V<sub>10</sub>O<sub>28</sub>·20H<sub>2</sub>O compound to prevent and efficiently treat the growth and metastasis of melanoma.

Authors

Institutions

Publication Details

Journal
Bioinorganic Chemistry and Applications
Published
2025-01-01
DOI
https://doi.org/10.1155/bca/6680022
Citations
2
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
1.35

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Decavanadate Compound Displays In Vitro and In Vivo Antitumor Effect on Melanoma Models

Amine Essid, Wassim Moslah, José Luis, Raoudha Doghri et al.
2 citations
Bioinorganic Chemistry and Applications
Nanoplatforms for cancer theranostics
1.35
article

Decavanadate Compound Displays In Vitro and In Vivo Antitumor Effect on Melanoma Models

Amine Essid, Wassim Moslah, José Luis, Raoudha Doghri, Ines ELBini-Dhouib, Regaya Ksiksi, Najet Srairi‐Abid, Imen Jendoubi, Mohamed-Faouzi Zid, Nardine Harrab
article en
2 citations

Abstract

The efficacy of available treatments for melanoma is limited by side effects and the rapidly emerging resistance to treatment. In this context, the decavanadate compounds represent promising tools to design efficient therapeutic agents. In our study, we synthesized a dimagnesium disodium decavanadate icosahydrate compound (Mg<sub>2</sub>Na<sub>2</sub>V<sub>10</sub>O<sub>28</sub>·20H<sub>2</sub>O) and investigated its structure stability as well as its antimelanoma effects. Results showed that the Mg<sub>2</sub>Na<sub>2</sub>V<sub>10</sub>O<sub>28</sub>·20H<sub>2</sub>O compound is structured in a monoclinic system with the space group C2/c, stabilized by oxygen vertices, hydrogen bonds, and van der Waals interactions. Interestingly, we found that this newly synthesized compound reduced the viability of human (IGR39, IGR37, and SKMEL28) and murine (B16-F10) melanoma cells in a dose-dependent manner. The IC<sub>50</sub> values ranged from 7.3 to 18 μM after 24 h and decreased to 1.4 μM after 72 h of treatment. Notably, this effect was more important than that of cisplatin (IC<sub>50</sub> = 3 μM after 72 h of treatment), a chemotherapeutic agent, commonly used in the treatment of malignant melanoma. Furthermore, the cytotoxicity of the decavanadate compound was relatively weak on normal human keratinocytes (HaCaT), with a light effect (IC<sub>50</sub> >> 70 μM) observed after 24 h of treatment. Thus, the Mg<sub>2</sub>Na<sub>2</sub>V<sub>10</sub>O<sub>28</sub>·20H<sub>2</sub>O compound displayed an advantage over cisplatin, which was reported to be much more aggressive to the keratinocyte cell line (IC<sub>50</sub> = 23.9 μM). Moreover, it inhibited dose-dependently the adhesion of IGR39 cells to collagen (IC<sub>50</sub> = 2.67 μM) and fibronectin, as well as their migration with an IC<sub>50</sub> value of 2.23 μM. More interestingly, its in vivo administration to B16-F10 allografted mice, at the nontoxic dose of 50 μg (2.5 mg/kg), prevented and suppressed by 70% the tumor growth, compared to the nontreated mice. Moreover, this compound has also allowed a recovery against inflammation induced in mice by a mixture of DMBA and croton oil. Thus, all our results showed the potential of the Mg<sub>2</sub>Na<sub>2</sub>V<sub>10</sub>O<sub>28</sub>·20H<sub>2</sub>O compound to prevent and efficiently treat the growth and metastasis of melanoma.

Bioinorganic Chemistry and ApplicationsVol. 2025(1)
Centre National de la Recherche Scientifique (FR), Aix-Marseille Université (FR), Institut Salah-Azaïz (TN), Institut de Neurophysiopathologie (FR), Institut Pasteur de Tunis (TN), Tunis El Manar University (TN)
Ministère de l’Enseignement Supérieur et de la Recherche Scientifique, Centre National de la Recherche Scientifique, Institut Pasteur de Tunis
Good health and well-being
Openalex Percentile: Top 23%
Nanoplatforms for cancer theranostics
1.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.